Talazoparib specifically is a prescription drug used for the treatment of adults with a certain type of breast cancer (gBRCA-mutated, HER2-) that has spread to other organs of the body (locally advanced or metastatic).
Dosage: The recommended dose is talazoparib 1 mg taken as a single oral daily dose, with or without food. Patients should be treated until the disease remains progressive or any kind of unacceptable toxicity is noticed. The hard pills (capsules) of talazoparib should be swallowed whole and must not be broken, opened or dissolved. If the patient misses or vomits a particular dose, an additional talazoparib dose should not be administered. The next prescribed dose should be administered at the usual time. The talazoparib 0.25 mg capsule is available for dose reduction.
Side Effects: The most commonly reported talazoparib side effects may include:
- Loss of appetite
- Hair loss
- Reduced RBC or WBC
- Low number of platelets
Warnings and Precautions:
Patients with talazoparib 1 mg therapy should be monitored for complete blood counts for cytopenia at baseline and monthly thereafter. Nursing mothers with talazoparib dosage are advised to not breastfeed their child during therapy. Male recipients with female partners of reproductive potential and pregnant partners must consider apt contraception during therapy with talazoparib and for at least 4 months after the last dose. Use of talazoparib capsules can cause fetal harm when administered to a pregnant woman.